Substances · Cathinone derivatives
α-PHP
- Preferred name
- α-PHP
- IUPAC name
- 1-phenyl-2-pyrrolidin-1-ylhexan-1-one
- Parent CAS number (reference)
- 13415-86-6
- Molecular formula
- C16H23NO
- Molecular weight
- 245.36 g/mol
- InChIKey
- KYIJLDDXQWBNGX-UHFFFAOYSA-N
- PubChem
- CID 102107923
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
alpha-PHP a-PHP aPHP alpha-pyrrolidinohexiophenone PV-7
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
alpha-PHP (alpha-Pyrrolidinohexiophenone / PV-7)
Receptor Telemetry & Mechanism of Action
Straight-chain six-carbon homologue of alpha-PVP (and chain isomer of alpha-PiHP) acting as a potent norepinephrine-dopamine reuptake inhibitor with a DAT/SERT selectivity ratio > 1,000 (0.06 at DAT and 0.06 at NET vs. 245 at SERT in comparative pyrovalerone transporter assays). Uniquely among close siblings, alpha-PHP also antagonizes human M1 and M2 muscarinic acetylcholine receptors, intensifying xerostomia (dry mouth), tachycardia, urinary difficulty, and delirium risk at heavy exposures.
Biotransformation & Active Metabolites
Human urinary studies identify 11 Phase I and 5 Phase II metabolites dominated by dihydroxy-pyrrolidinyl-alpha-PHP (M5, 45.1%) and dihydro-alpha-PHP (M1, 25.5%). WHO 42nd ECDD highlights an extended half-life contributing to long-lasting psychotic symptoms; confirmed to cross the placenta.
Temporal Pharmacokinetics
Powerful, forced catecholaminergic stimulation with full-body mood-elevating tingling, narrow task fixation, topical mouth/nasal numbing, and a slightly less sharp initial rush than alpha-PVP paired with a longer wakefulness tail.
- Onset 2–20 minutes oral
- Peak Window 1–2.5 hours
- Total Window 2–8 hours oral
- Residual / Half-Life 1–48 hours of residual wakefulness, tachycardia, and potential long-lasting psychotic symptoms (extended half-life noted by WHO 42nd ECDD; exact numerical plasma t1/2 unverified).
Milligram potency matches alpha-PVP (common oral 10–25 mg; mucosal 10–20 mg; vaporized 6–15 mg), while residual stimulation can linger up to 48 hours. repeated exposure before residual levels clear stacks sudden blood-pressure surges ('exploding heart' sensation), intense vasoconstriction, tremors, and long-lasting paranoid psychosis.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
1–5 mg oral (mucosal: 2–4 mg; vaporized: 1–2 mg)
Subtle mental sharpening, alertness, and reduced drowsiness.
Mild pulse elevation and faint dry mouth.
5–10 mg oral (PMC11051472 5–15 mg; mucosal: 4–10 mg; vaporized: 3–6 mg)
Strong wakefulness, narrow task focus, talkativeness, and confident mood lift.
Noticeable heart-rate increase, dry mouth, and appetite suppression.
10–25 mg oral (mucosal: 10–20 mg; vaporized: 6–15 mg)
Intense mood-elevating body tingling, hyper-fixation on repetitive tasks, tactile enhancement, and strong urge to redose.
Marked tachycardia, elevated blood pressure, strong dry mouth, sweating, jaw clenching, and local mucosal numbing.
25–40 mg oral (mucosal: 20–35 mg; vaporized: 15–25 mg)
Forced restlessness, hand unsteadiness, nystagmus (blurry vibrating vision), anxiety, and paranoid hyper-vigilance.
Severe peripheral vasoconstriction, sudden blood-pressure spikes, difficulty urinating, muscle spasms, and prolonged insomnia.
40+ mg oral (mucosal: 35+ mg; vaporized: 25+ mg)
Long-lasting paranoid psychosis, hallucinations, agitation, delirium, or somnolent unresponsiveness.
Dangerous hypertension, cardiac arrest, hyperthermia, rhabdomyolysis, seizures, and intrauterine fetal asphyxia in pregnancy.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Potent DAT/NET blockade combined with MAO inhibition causes fatal hypertensive crisis, stroke, and hyperthermia.
Synergistic vasoconstriction, muscarinic-antagonist tachycardia, malignant hypertension, and cardiac arrest.
Tramadol induces seizures; co-consumed opiates (detected in 60% of a 29-case clinical/forensic alpha-PHP series) cause severe poly-intoxication and respiratory arrest.
Elevated Hazard — Avoid
Compounds alpha-PHP's intrinsic M1/M2 muscarinic antagonism, worsening tachycardia, hyperthermia, urinary retention, and delirium.
Masks depressant intoxication, accelerates severe dehydration, and increases collapse risk; strictly contraindicated in pregnancy.
Caution / Receptor Attenuation
Frequently precipitates acute paranoia, racing pulse, and hallucinations during alpha-PHP's long offset.
Intensifies tremors, palpitations, and restless leg symptoms.
Structural Isomer & Sibling Comparison
alpha-PHP (PV-7) is the straight-chain 6-carbon homologue of alpha-PVP and positional chain isomer of alpha-PiHP. PsychonautWiki notes alpha-PHP is slightly less aggressively stimulating at onset than alpha-PVP while sharing identical oral milligram brackets (10–25 mg common), lasting longer (2–8 h vs. 2–6 h) with a longer residual tail (up to 48 h) and extra M1/M2 muscarinic dry-mouth/urinary effects. Compared to alpha-PiHP, alpha-PHP is longer-acting (2–8 h vs. 2–5 h).
Physicochemical Stability & Storage
Form: Transparent to whitish or pale yellowish crystals, or beige/off-white crystalline powder (HCl salt) with a bitter taste and topical mucosal numbing. · Soluble in water/PBS, ethanol, methanol, DMF, and DMSO.
Store sealed in an airtight, light-protected container in a cool, dry place.
Cross-Tolerance & Dependence Profile
Very high abuse and psychological dependence liability; rapid tolerance within a single session and full cross-tolerance with alpha-PVP, alpha-PiHP, MDPHP, Hexen, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).
Chemical Architecture & Structural Profile
α-PHP (1-phenyl-2-pyrrolidin-1-ylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C16H23NO and a molar mass of 245.36 g/mol. The parent molecule is indexed under CAS registry number 13415-86-6 and in the NCBI PubChem database as CID 102107923 (Standard InChIKey: KYIJLDDXQWBNGX-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PHP is indexed within the Cathinone, Substituted cathinones, Substituted pyrrolidines structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): highly addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- legislation.gov.uk — Misuse of Drugs Act 1971 & Psychoactive Substances Act 2016 — The National Archives (UK) (2026-11-12)